Cytogen

Cytogen Gross Margin

The Gross Margin of Cytogen (217330.KQ) as of Oct 19, 2026 is 21.55 %. In the previous year, Gross Margin was 25.93 % — a change of -16.89% (lower).

Gross Margin

21.55 %

YoY

-16.89%

Last updated:

Gross Margin of Cytogen is 2025 21.55 % . Gross Margin of Cytogen was 2024 25.93 % . It decreases by -16.89% lower compared to the previous year.

Cytogen's gross margin stands at 21.6%, up from 16.5% several years earlier.

The Cytogen Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
25.47 KRW
Jan 1, 2019
-23.37 KRW
Jan 1, 2020
-20.17 KRW
Jan 1, 2021
16.47 KRW
Jan 1, 2022
25.66 KRW
Jan 1, 2023
26.57 KRW
Jan 1, 2024
25.93 KRW
Jan 1, 2025
21.55 KRW
The Cytogen Gross Margin history
YEARGross MarginYoY
21.55 %-16.89%
25.93 %-2.42%
26.57 %+3.58%
25.66 %+55.81%
16.47 %-181.64%
-20.17 %-13.69%
-23.37 %-191.74%
25.47 %+98.77%
12.81 %-58.58%
30.94 %+141.22%
12.83 %+104.48%
6.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytogen Stock analysis

What does Cytogen do? Cytogen Inc, listed on the Korean stock market with ticker 217330.KQ and ISIN KR727330000, is a biotechnology company based in Seoul, South Korea. The company, which went public on November 22, 2018, employs 43 full-time staff. Cytogen Inc focuses on the research and development of cancer treatment solutions, particularly in the field of liquid biopsy applications. Its services include biomarker discovery and verification, such as circulating tumor cell (CTC)-based biomarker analysis, gene mutation and transcript expression studies, and drug testing. The company also provides liquid biopsy-based precision medical services, including companion diagnostics development, therapeutic drug re-selection, treatment effectiveness monitoring, and recurrence prediction. Cytogen Inc develops and sells platforms and kits for liquid biopsy, distributing its products domestically in South Korea and internationally. The company's website is http://www.cytogenlab.com. As a biotechnology firm operating within the healthcare sector, Cytogen Inc is engaged in advancing cancer diagnostics and treatment through innovative liquid biopsy technologies. Cytogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytogen stock

Gross Margin of Cytogen is 21.55 % in 2025.

Gross Margin of Cytogen changed from 25.93 % to 21.55 %, representing a -16.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Cytogen since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Cytogen with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cytogen

All Key Metrics — Cytogen